Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.

Indaptus Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY INITIATES COMBINATION TRIAL AND STRENGTHENS BALANCE SHEET TO SUPPORT CONTINUED CLINICAL PROGRESS COMPANY INITIATES COMBINATION TRIAL AND STRENGTHENS BALANCE SHEET TO SUPPORT CONTINUED CLINICAL PROGRESS

INDAPTUS THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEW YORK, JULY 01, 2025 (GLOBE NEWSWIRE) -- INDAPTUS THERAPEUTICS, INC. (NASDAQ: INDP) (INDAPTUS), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEDICATED TO PIONEERING INNOVATIVE CANCER AND VIRAL INFECTION TREATMENTS, TODAY ANNOUNCED THE ADDITIONAL SALE OF APPROXIMATELY $3.4 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE PROMISSORY NOTES AND ACCOMPANYING WARRANTS. TOGETHER WITH A PRIOR SALE OF $2.3 MILLION OF CONVERTIBLE PROMISSORY NOTES AND ACCOMPANYING WARRANTS, THE COMPANY RAISED AN AGGREGATE OF $5.7 MILLION IN GROSS PROCEEDS IN THIS OFFERING.

INDAPTUS THERAPEUTICS, INC. ANNOUNCES ADDITIONAL SALE OF $3.4 MILLION IN PRIVATE PLACEMENT OF CONVERTIBLE NOTES AND WARRANTS

NEW YORK, JUNE 25, 2025 (GLOBE NEWSWIRE) -- INDAPTUS THERAPEUTICS, INC. (NASDAQ: INDP) (INDAPTUS OR THE COMPANY), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEDICATED TO PIONEERING INNOVATIVE CANCER AND VIRAL INFECTION TREATMENTS, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS APPROVED A ONE-FOR-TWENTY EIGHT REVERSE STOCK SPLIT OF ITS COMMON STOCK THAT IS SCHEDULED TO BECOME EFFECTIVE AFTER TRADING CLOSES ON JUNE 26, 2025. BEGINNING ON JUNE 27, 2025, THE COMPANY'S COMMON STOCK WILL TRADE ON THE NASDAQ CAPITAL MARKET ON A SPLIT ADJUSTED BASIS UNDER A NEW CUSIP NUMBER 45339J 204.

INDAPTUS THERAPEUTICS ANNOUNCES REVERSE STOCK SPLIT

NEW YORK, JUNE 13, 2025 (GLOBE NEWSWIRE) -- INDAPTUS THERAPEUTICS, INC. (NASDAQ: INDP) (INDAPTUS), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEDICATED TO PIONEERING INNOVATIVE CANCER AND VIRAL INFECTION TREATMENTS, TODAY ANNOUNCED THE SALE OF APPROXIMATELY $2.3 MILLION IN AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE PROMISSORY NOTES AND ACCOMPANYING WARRANTS. THIS TRANSACTION IS BEING LED BY A HEALTHCARE-FOCUSED INSTITUTIONAL INVESTOR IN AN ONGOING OFFERING IN WHICH THE COMPANY IS SEEKING TO RAISE UP TO $5 MILLION IN GROSS PROCEEDS.

INDAPTUS THERAPEUTICS, INC. ANNOUNCES SALE OF $2.3 MILLION IN PRIVATE PLACEMENT OF CONVERTIBLE NOTES AND WARRANTS

NEW YORK, JUNE 02, 2025 (GLOBE NEWSWIRE) -- INDAPTUS THERAPEUTICS, INC. (NASDAQ: INDP), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING NOVEL TREATMENTS FOR CANCER AND VIRAL INFECTIONS, ANNOUNCES THAT THE FIRST PATIENT HAS BEEN DOSED IN THE EXPANSION ARM OF ITS PHASE 1B/2 CLINICAL TRIAL EVALUATING DECOY20 IN COMBINATION WITH BEONE'S (FORMERLY KNOWN AS BEIGENE) PD-1 CHECKPOINT INHIBITOR, TISLELIZUMAB. THIS NEWLY ACTIVATED ARM OF THE TRIAL WILL ASSESS SAFETY, DOSE OPTIMIZATION, AND EARLY SIGNS OF ANTI-TUMOR ACTIVITY IN PATIENTS WITH ADVANCED SOLID TUMORS, PREVIOUSLY TREATED WITH A CHECKPOINT INHIBITOR OR WITH TUMORS TYPICALLY UNRESPONSIVE TO A CHECKPOINT INHIBITOR.

INDAPTUS THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1B/2 COMBINATION STUDY OF DECOY20 WITH PD-1 CHECKPOINT INHIBITOR TISLELIZUMAB

NEW YORK, MAY 14, 2025 (GLOBE NEWSWIRE) -- INDAPTUS THERAPEUTICS, INC. (NASDAQ: INDP) (INDAPTUS OR THE COMPANY), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEDICATED TO PIONEERING INNOVATIVE CANCER AND VIRAL INFECTION TREATMENTS, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A CORPORATE UPDATE.

INDAPTUS THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

NEW YORK, MAY 08, 2025 (GLOBE NEWSWIRE) -- INDAPTUS THERAPEUTICS, INC. (NASDAQ: INDP), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING NOVEL TREATMENTS FOR CANCER AND VIRAL INFECTIONS, ANNOUNCES THAT ITS FOUNDER AND CHIEF SCIENTIFIC OFFICER, MICHAEL NEWMAN, PH.D., WILL SERVE AS AN EXPERT SPEAKER AND CHAIR OF DAY 2 AT THE 6TH ANNUAL CYTOKINE-BASED DRUG DEVELOPMENT SUMMIT TAKING PLACE MAY 15-16, 2025 IN BOSTON.

INDAPTUS THERAPEUTICS FOUNDER AND CHIEF SCIENTIFIC OFFICER DR. MICHAEL NEWMAN NAMED CHAIR AND EXPERT SPEAKER AT 6TH ANNUAL CYTOKINE-BASED DRUG DEVELOPMENT SUMMIT

NEW YORK, MARCH 25, 2025 (GLOBE NEWSWIRE) -- INDAPTUS THERAPEUTICS, INC. (NASDAQ: INDP), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING INNOVATIVE THERAPIES FOR CANCER AND VIRAL INFECTIONS, ANNOUNCES THAT ITS CHIEF MEDICAL OFFICER, ROGER WALTZMAN, M.D., M.B.A. WILL BE MODERATING A PANEL AT THE ANNUAL CMO360 SUMMIT, BEING HELD APRIL 7-8 IN BOSTON.

INDAPTUS THERAPEUTICS CHIEF MEDICAL OFFICER ROGER WALTZMAN, M.D., M.B.A. TO MODERATE PANEL AT CMO360 SUMMIT

NEW YORK, MARCH 20, 2025 (GLOBE NEWSWIRE) -- INDAPTUS THERAPEUTICS, INC. (NASDAQ: INDP), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING NOVEL TREATMENTS FOR CANCER AND VIRAL INFECTIONS, TODAY PROVIDED AN UPDATE ON KEY PHARMACODYNAMIC FINDINGS FROM THE WEEKLY DOSING COHORT OF ITS ONGOING PHASE 1 TRIAL OF DECOY20. AS ANNOUNCED IN LAST WEEK'S EARNINGS RELEASE, THE COMPANY HAS NOW ENROLLED MORE THAN 20 PATIENTS IN THE WEEKLY DOSING COHORT, MARKING A KEY MILESTONE IN THE TRIAL.

INDAPTUS THERAPEUTICS REPORTS NEW DATA DEMONSTRATING SUCCESSFUL BROAD IMMUNE SYSTEM ACTIVATION IN WEEKLY DOSING TRIAL OF DECOY20

NEW YORK, MARCH 18, 2025 (GLOBE NEWSWIRE) -- INDAPTUS THERAPEUTICS, INC. (NASDAQ: INDP), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO DEVELOPING NOVEL TREATMENTS FOR CANCER AND VIRAL INFECTIONS, TODAY ANNOUNCED THAT IT HAS ADVANCED TOA NEW EXPANSION ARM OF ITS PHASE 1B/2 CLINICAL TRIAL OF DECOY20. THIS EXPANSION WILL EVALUATE THE COMBINATION OF DECOY20 WITH BEIGENE'S PD-1 CHECKPOINT INHIBITOR, TISLELIZUMAB, WITH A FOCUS ON SAFETY, DOSE OPTIMIZATION, AND EARLY SIGNS OF ANTI-TUMOR ACTIVITY.

INDAPTUS THERAPEUTICS INITIATES PHASE 1 COMBINATION STUDY OF DECOY20 WITH PD-1 CHECKPOINT INHIBITOR TISLELIZUMAB

NEW YORK, MARCH 13, 2025 (GLOBE NEWSWIRE) -- INDAPTUS THERAPEUTICS, INC. (NASDAQ: INDP) (INDAPTUS OR THE COMPANY) TODAY ANNOUNCES FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED DECEMBER 31, 2024 AND PROVIDES A CORPORATE UPDATE.

Indaptus Therapeutics, Inc.

INDP

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Indaptus Therapeutics, Inc.

INDP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

INDP